This trial is concluded. This means the trial has been completed. The results of the trial are summarised in the 'results' section of this page. You cannot enrol in this trial.
About this trial
This study is looking at a new drug - SCH 532706 - from the new class of CCR5 inhibitors or antagonists.
SCH 532706 is taken twice daily (with a low dose of ritonavir taken once daily) over 10 days. The purpose is to look at how effective the combination is at suppressing HIV as well as how safe and easy it is to take.
Background information
CCR5 inhibitors block the CCR5 co-receptor, one of two chemical doorways that HIV uses to enter and infect the cell (the other is called CXCR4).
CCR5 inhibitors work specifically against CCR5-tropic HIV, but some people have CXCR4-tropic HIV (meaning their strain[HIV strain] Any subgroup of the HIV species. Because HIV mutates very easily, there are many different strains (and may be multiple strains within a single person). of HIV uses the other co-receptor) or a dual/mixed-tropic virusA small infective organism which is incapable of reproducing outside a host cell. (meaning their virus uses both).
Usually, CCR5-tropic HIV predominates during early infection while CXCR4-tropic HIV appears later and is associated with more advanced disease.
Before being treated with a CCR5 inhibitor you need to have a test to determine whether you have the right strain of virus this drug classA group of anti-HIV drugs with the same target of action. Anti-HIV drug classes include nucleoside analogue reverse transcriptase inhibitors, protease inhibitors and non-nucleoside analogue reverse transcriptase inhibitors, as well as several others. Combining drugs from three or more classes is the basis of Highly Active Antiretroviral Therapy (HAART). will affect.
| Official title: | Activity and Safety of SCH 532706 in HIV-1 Infected Subjects |
|---|
| What is this trial studying? | New drug – SCH532706 |
|---|
| Start date: | March 2007 (closed in July 2007) This may be the proposed or expected start date for trials which have not yet started. |
|---|
| How many participants will this trial enrol? | 12 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
|---|
| How long is this trial planned to go for? | Participants in this trial will be asked to take the trial drug for 10 days. |
|---|
| Links to further information: | |
|---|
| Can I access this treatment other than by enrolling in this trial? | No.
|
|---|
Who can enrol in this trial?
You may be eligible to participate in this trial if you meet the following criteria:
- At least 18 years old
- You must have CCR5 tropism
You
will not be eligible to participate in this trial if you meet any of the following criteria:
- Have taken HIV treatments in the past
This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.
Results:
See above link for poster presentation from 15th Conference on Retroviruses and Opportunistic Infections (CROI) 2008
This site complies with the HONcode standard for trustworthy health information: verify here. 
